Platonov A E, Vershinina I V, Käyhty H, Fijen C A, Kuijper E J
Central Research Institute of Epidemiology, Moscow, Russia.
Zh Mikrobiol Epidemiol Immunobiol. 1999 May-Jun(3):46-52.
32 Russian patients with late complement component deficiency (LCCD) were immunize with tetravalent meningococcal polysaccharide vaccine (A + C + W135 + Y). Their immune response and infectious morbidity rate were followed for 6 years and the partial protective efficacy of vaccination was demonstrated. As the antibody-mediated complement-induced bactericidal activity of plasma was completely absent in persons with LCCD, the bactericidal action of human neutrophils on meningococci of groups A, W135 and B was studied under the conditions of incubation with serum samples collected from persons with LCCD before and after vaccination. In LCCD serum alone the exponential growth of meningococci was observed, while the addition of human neutrophils resulted in the essential inhibition of the growth of meningococci (up to their complete elimination). The proportion of serum samples stimulating the elimination of group A and W 135 meningococci by neutrophils was almost 40% of the serum samples collected before vaccination and significantly increased among the serum samples collected after vaccination (up to 84%) or revaccination (up to 90%). At the same time the capacity of an individual serum sample to promote the bactericidal effect of neutrophils against meningococci correlated with its content of specific anti-polysaccharide IgG and IgM antibodies, as well as antibodies to the inner core of lipopolysaccharide. The interaction of neutrophils with meningococci was significantly inhibited after incubation in heat-inactivated serum, suggesting that this interaction was partly mediated along the following path: the binding of IgM and IgG antibodies with bacteria--the activation of complement and the deposition of C3 complement on bacteria--the binding of meningococci with CR3 receptors of neutrophils.
32例晚期补体成分缺陷（LCCD）的俄罗斯患者接种了四价脑膜炎球菌多糖疫苗（A + C + W135 + Y）。对他们的免疫反应和感染发病率进行了6年的跟踪观察，证实了疫苗接种具有部分保护效果。由于LCCD患者血浆中完全缺乏抗体介导的补体诱导杀菌活性，因此研究了人类中性粒细胞在与LCCD患者接种疫苗前后采集的血清样本孵育条件下对A、W135和B群脑膜炎球菌的杀菌作用。单独使用LCCD血清时，观察到脑膜炎球菌呈指数生长，而加入人类中性粒细胞后，脑膜炎球菌的生长受到显著抑制（直至完全消除）。刺激中性粒细胞消除A群和W135群脑膜炎球菌的血清样本比例在接种疫苗前采集的血清样本中约为40%，在接种疫苗后（高达84%）或再次接种疫苗后（高达90%）采集的血清样本中显著增加。同时，个体血清样本促进中性粒细胞对脑膜炎球菌杀菌作用的能力与其特异性抗多糖IgG和IgM抗体以及脂多糖内核抗体的含量相关。在热灭活血清中孵育后，中性粒细胞与脑膜炎球菌的相互作用受到显著抑制，这表明这种相互作用部分是沿着以下途径介导的：IgM和IgG抗体与细菌结合——补体激活和C3补体在细菌上沉积——脑膜炎球菌与中性粒细胞的CR3受体结合。
